vs
ABVC BIOPHARMA, INC.（ABVC）与SenesTech, Inc.（SNES）财务数据对比。点击上方公司名可切换其他公司
ABVC BIOPHARMA, INC.的季度营收约是SenesTech, Inc.的1.9倍（$796.0K vs $421.0K），ABVC BIOPHARMA, INC.净利率更高（-256.6% vs -428.5%，领先171.9%），ABVC BIOPHARMA, INC.同比增速更快（104.5% vs -16.0%），过去两年ABVC BIOPHARMA, INC.的营收复合增速更高（1041.5% vs 0.7%）
ABVC生物制药是一家处于临床阶段的生物制药企业，专注于开发肿瘤、眼科、中枢神经系统疾病等领域的创新治疗方案，业务覆盖北美及亚洲主要市场，多款自研候选药物正处于临床试验推进阶段。
SenesTech是一家农业生物技术生命科学企业，专注于通过生育调控实现害鼠防治。公司核心产品ContraPest可使褐家鼠与黑家鼠丧失生育能力，以此达到控鼠效果，公司总部位于美国亚利桑那州凤凰城。
ABVC vs SNES — 直观对比
营收规模更大
ABVC
是对方的1.9倍
$421.0K
营收增速更快
ABVC
高出120.4%
-16.0%
净利率更高
ABVC
高出171.9%
-428.5%
两年增速更快
ABVC
近两年复合增速
0.7%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $796.0K | $421.0K |
| 净利润 | $-2.0M | $-1.8M |
| 毛利率 | 100.0% | 55.3% |
| 营业利润率 | -246.8% | -446.8% |
| 净利率 | -256.6% | -428.5% |
| 营收同比 | 104.5% | -16.0% |
| 净利润同比 | -417.4% | -43.7% |
| 每股收益（稀释后） | $-0.09 | $0.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABVCSNES
| Q4 25 | — | $421.0K | ||
| Q3 25 | $796.0K | $690.0K | ||
| Q2 25 | — | $625.0K | ||
| Q1 25 | — | $485.0K | ||
| Q4 24 | $2.0K | $501.0K | ||
| Q3 24 | $389.3K | $482.0K | ||
| Q2 24 | $117.1K | $459.0K | ||
| Q1 24 | $1.2K | $415.0K |
净利润ABVCSNES
| Q4 25 | — | $-1.8M | ||
| Q3 25 | $-2.0M | $-1.3M | ||
| Q2 25 | — | $-1.6M | ||
| Q1 25 | — | $-1.7M | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | $-394.8K | $-1.5M | ||
| Q2 24 | $-942.3K | $-1.6M | ||
| Q1 24 | $-2.8M | $-1.8M |
毛利率ABVCSNES
| Q4 25 | — | 55.3% | ||
| Q3 25 | 100.0% | 62.8% | ||
| Q2 25 | — | 65.4% | ||
| Q1 25 | — | 64.5% | ||
| Q4 24 | 100.0% | 60.9% | ||
| Q3 24 | 99.9% | 65.4% | ||
| Q2 24 | 99.8% | 54.2% | ||
| Q1 24 | 77.0% | 32.5% |
营业利润率ABVCSNES
| Q4 25 | — | -446.8% | ||
| Q3 25 | -246.8% | -195.2% | ||
| Q2 25 | — | -258.2% | ||
| Q1 25 | — | -342.9% | ||
| Q4 24 | — | -250.9% | ||
| Q3 24 | -77.7% | -321.0% | ||
| Q2 24 | -734.2% | -349.0% | ||
| Q1 24 | -235539.8% | -444.1% |
净利率ABVCSNES
| Q4 25 | — | -428.5% | ||
| Q3 25 | -256.6% | -188.1% | ||
| Q2 25 | — | -258.6% | ||
| Q1 25 | — | -343.3% | ||
| Q4 24 | — | -250.5% | ||
| Q3 24 | -101.4% | -313.9% | ||
| Q2 24 | -804.4% | -345.1% | ||
| Q1 24 | -235203.2% | -441.4% |
每股收益（稀释后）ABVCSNES
| Q4 25 | — | $0.48 | ||
| Q3 25 | $-0.09 | $-0.28 | ||
| Q2 25 | — | $-0.87 | ||
| Q1 25 | — | $-1.28 | ||
| Q4 24 | — | $-0.15 | ||
| Q3 24 | $-0.03 | $-2.07 | ||
| Q2 24 | $-0.08 | $-3.08 | ||
| Q1 24 | $-0.29 | $-3.56 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $257.2K | $8.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $12.1M | $9.6M |
| 总资产 | $21.2M | $12.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABVCSNES
| Q4 25 | — | $8.6M | ||
| Q3 25 | $257.2K | $10.2M | ||
| Q2 25 | — | $6.1M | ||
| Q1 25 | — | $1.7M | ||
| Q4 24 | $313.1K | $1.3M | ||
| Q3 24 | $208.2K | $2.5M | ||
| Q2 24 | $200.0K | $2.0M | ||
| Q1 24 | $106.4K | $3.6M |
股东权益ABVCSNES
| Q4 25 | — | $9.6M | ||
| Q3 25 | $12.1M | $11.3M | ||
| Q2 25 | — | $7.0M | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | $1.2M | $2.5M | ||
| Q3 24 | $1.6M | $3.7M | ||
| Q2 24 | $1.8M | $3.1M | ||
| Q1 24 | $1.7M | $4.6M |
总资产ABVCSNES
| Q4 25 | — | $12.8M | ||
| Q3 25 | $21.2M | $14.6M | ||
| Q2 25 | — | $10.4M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | $7.5M | $3.3M | ||
| Q3 24 | $7.8M | $4.4M | ||
| Q2 24 | $8.0M | $4.0M | ||
| Q1 24 | $8.0M | $5.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-964.7K | $-1.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-1.7M |
| 自由现金流率自由现金流/营收 | — | -398.3% |
| 资本支出强度资本支出/营收 | — | 3.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-5.9M |
8季度趋势，按日历期对齐
经营现金流ABVCSNES
| Q4 25 | — | $-1.7M | ||
| Q3 25 | $-964.7K | $-1.4M | ||
| Q2 25 | — | $-1.1M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | $-1.8M | $-1.2M | ||
| Q3 24 | $60.2K | $-1.4M | ||
| Q2 24 | $-211.4K | $-1.6M | ||
| Q1 24 | $-955.8K | $-1.8M |
自由现金流ABVCSNES
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-1.8M |
自由现金流率ABVCSNES
| Q4 25 | — | -398.3% | ||
| Q3 25 | — | -205.9% | ||
| Q2 25 | — | -191.5% | ||
| Q1 25 | — | -328.5% | ||
| Q4 24 | — | -246.1% | ||
| Q3 24 | — | -296.1% | ||
| Q2 24 | — | -354.2% | ||
| Q1 24 | — | -441.2% |
资本支出强度ABVCSNES
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | 5.8% | ||
| Q2 24 | — | 8.5% | ||
| Q1 24 | — | 0.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
